No abstract available.
Tachycardia, Supraventricular* ; Tachycardia, Ventricular*

To increase the success rate of intraocular pressure control in recalcitrant glaucoma, Ahmed glaucoma shunt has been used recently. Application of mitomycin C(MMC) during Ahmed implantation may be speculated to increase the success rate by decreasing the fibroblast proliferation and colagen deposition in the filtering capsule. To find out histological change with the use of MMC in the capsule of seton implant, a rabbit model of the Ahmed implant was created to obtain a serial histological specimens over 6 months. Ahmed S1 implant were implanted in 10 normal white rabbits. Five rabbits were treated with 0.04% MMC solution during the implantation under subtenon space(group 1) and the remaining ones were not(group 2). The rabbits were sacrificed at 1, 3, and 6 months to obtain histological specimen of the bleb capsules in each group. Light microscopic examinations were performed after hematoxylin and eosin staining. In group 1(MMC application group), the thickness of fibrous capsule was 0.6mm at 1 month, 0.48mm at 3 months, and 0.4mm at 6 months serially. The number of fibroblasts was 139/mm3 at 1 month, and 82/mm3 at 6 months. In group 2, the capsule thickness was not significantly different compared with roup 1 at 6 months. IN conclusion, during the period over 6 months period, there was no significant difference in thickness of bleb capsule in the two groups although the number of fibroblasts was 3 times denser in group 2 than in group 1.
Blister ; Capsules ; Eosine Yellowish-(YS) ; Fibroblasts ; Glaucoma ; Hematoxylin ; Intraocular Pressure ; Mitomycin* ; Rabbits

No abstract available.
Administration, Intravenous* ; Cervix Uteri* ; Cisplatin* ; Female ; Fluorouracil*

Priapism is defined as a prolonged erection of the penis unrelated to sexual desire or manual stimulation. Non-ischemic priapism frequently occurs as a result of penile or perineal trauma, but the unknown etiology is rare in boys. We report a case in a 6-year-old boy who was managed successfully with conservative treatment consisting of steroid tapering and perineal ice-pack compression therapy following blood gas analysis of the cavernosum and penile duplex ultrasonography. Complete detumescence was achieved after two weeks. Thus far, the patient has had no recurrence for 6 months.
Blood Gas Analysis ; Child* ; Humans ; Male ; Pediatrics ; Penis ; Priapism* ; Recurrence ; Ultrasonography

PURPOSE: This study was performed to investigate the availability of the serum HSP72 and HSP27 as serologic markers of cardiac allograft rejection through rat heterotopic heart transplatation model. METHODS: Inbred Lewis rats were randomly divided into three groups: the allograft heart transplant group, the isograft heart transplant group, and the sham-operated group. Six animals were studied in each group. In allograft heart tranplant group, the Brown Norway rats were used as donors and in isograft heart tranplant group, the Lewis rats were used as donors. The sera of the allograft heart transplanted rats, isograft heart transplanted rats, and sham- operated rats were collected at preoperative time, 3 days after operation and 6 days after operation, and analyzed for HSP72 and HSP27 by Western blots. Quantifications of band densities were carried out by laser densitometer and the results were expressed as % preoperative densities. RESULTS: The levels of serum HSP72 of 3 days and 6 days after heart transplantation significantly increased in the allograft heart transplant group than in the isograft heart transplant group, respectively (160.2+/-44.8% vs. 109.0+/-34.7%, 276.0+/-72.1% vs. 175.0+/-44.2%, P<0.05). The levels of seum HSP27 of 3 days and 6 days after heart transplantation significantly increased in the allograft heart transplant group than in the isograft heart transplant group, respectively (162.3+/-62.7% vs. 118.4+/-37.0%, 235.7+/-67.1% vs. 127.9+/-40.8%, P<0.05). CONCLUSION: It is concluded that serum HSP72 and HSP27 are useful markers to detect the cardiac allograft rejection.
Allografts ; Animals ; Blotting, Western ; Heart Transplantation ; Heart* ; Heat-Shock Proteins ; Humans ; Isografts ; Norway ; Rats* ; Rats, Inbred Lew ; Tissue Donors ; Transplantation

OBJECTIVES: DNA polymerase (pol) of Hepatitis B virus (HBV) includes 3 different domains such as terminal protein (TP), reverse transcriptase (RT) and RNase H. Humoral immune responses to each of these proteins have not been well documented previously, although antibody to pol was detected in serum of patients with chronic hepatitis B. We have constructed TP (amino acids 1-182), RT (amino acids 346-685) and RNase H (amino acids 690-832). METHODS: By ELISA using each protein expressed in E. coli as antigens, the corresponding antibodies were tested in serum from 40 patients with type B viral chronic liver diseases. (20 HBeAg-positive and 20 HBeAg-negative). As negative controls, sera from 3 healthy young men were used. With the mean values of the OD, which were tested 4 times per each test sample and 3 times per each control sample, we considered to be positive if the mean OD of each test sample is 2-fold or higher than that of controls. RESULTS: Five of 40 sera (12.5%) contained one or two different antibodies detectable by this method: 4 of 20 HbeAg-positive sera (20%) and 1 of 20 HbeAg-negative sera (5%). Anti-TP, anti-RT and anti-RNase H antibodies were detected in 2.5% (1/40), 10% (4/40) and 7.5% (3/40), respectively. Among 4/20 HbeAg-positive ELISA-positive sera, anti-TP, anti-RT and anti-RNase H were positive in 5% (1/20), 20% (4/20) and 10% (2/20), respectively, while 1 HBeAg-negative ELISA-positive sera were positive only for anti-RNase H. CONCLUSIONS: These results suggest that the corresponding antibody responses to individual recombinant peptides derived from 3 domains of DNA polymerase may tend to be detected more frequently in HBeAg-positive sera than in HBeAg-negative sera from various patients with type B viral chronic liver diseases.
Adult ; Antibodies, Antinuclear/analysis* ; Biological Markers/analysis ; DNA Polymerase II/immunology* ; Enzyme-Linked Immunosorbent Assay ; Female ; Hepatitis B Surface Antigens/analysis* ; Hepatitis B Virus/immunology* ; Hepatitis B, Chronic/immunology* ; Human ; Male ; Middle Age ; Odds Ratio ; Reference Values ; Substances: DNA Polymerase II ; Substances: Hepatitis B Surface Antigens ; Substances: Biological Markers ; Substances: Antibodies, Antinuclear

Cervical cancer is the fourth most lethal women's cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally. However, even though the commercially available prophylactic HPV vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), are effective in blocking the entry of HPV into the epithelium of cervix through generation of HPV-specific neutralizing antibodies, they cannot eliminate the pre-existing HPV infection. For these reason, other immunotherapeutic options against HPV-associated diseases, including therapeutic vaccines, have been continuously explored. Therapeutic HPV vaccines enhance cell-mediated immunity targeting HPV E6 and E7 antigens by modulating primarily dendritic cells and cytotoxic T lymphocyte. Our review will cover various therapeutic vaccines in development for the treatment of HPV-associated lesions and cancers. Furthermore, we will discuss the potential of immune checkpoint inhibitors that have recently been adopted and tested for their treatment efficacy against HPV-induced cervical cancer.
Dendritic Cells/immunology ; Female ; Genetic Vectors ; Humans ; *Immunotherapy ; Papillomavirus Infections/*complications/therapy ; Papillomavirus Vaccines/therapeutic use ; *Translational Medical Research ; Uterine Cervical Neoplasms/*therapy ; Vaccines, DNA/therapeutic use ; Vaccines, Subunit/therapeutic use

For patients with a spinal cord injury, assisted ejaculation procedures are recommended as the treatment of choice. If assisted ejaculation procedures fail or yield spermatozoa insufficient to assisted reproductive techniques, surgical sperm retrieval is indicated. A total of 7 patients with a spinal cord injury, who still failed to obtain pregnancy after assisted ejaculation procedures, were treated in our clinic with the in vitro retrieval of epididymal sperm. The efficacy of in vitro retrieval of epididymal sperm was evaluated.
Ejaculation ; Humans ; Infertility, Male ; Male ; Pregnancy ; Reproductive Techniques, Assisted ; Sperm Retrieval ; Spermatozoa* ; Spinal Cord Injuries* ; Spinal Cord*

While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectropheresis of pleural fluid. Transient improvement of the pleural effusion was observed after administration of combination chemotherapy of vincristine, melphalan, cyclophosphamide, prednisone (VMCP)/vincristine, cyclophosphamide, adriamycin, prednisone (VCAP). Two months later, myelomatous pleural effusion recurred and no response to salvage therapy was observed. We reviewed the clinical feature of this case and literature concerning myelomatous pleural effusion.
Antineoplastic Agents, Combined/administration & dosage* ; Case Report ; Cyclophosphamide/administration & dosage ; Female ; Human ; Melphalan/administration & dosage ; Middle Age ; Multiple Myeloma/pathology ; Multiple Myeloma/drug therapy* ; Multiple Myeloma/complications* ; Plasma Cells/pathology ; Pleural Effusion/radiography ; Pleural Effusion/pathology ; Pleural Effusion/etiology* ; Prednisone/administration & dosage ; Tomography, X-Ray Computed ; Vincristine/administration & dosage

While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectropheresis of pleural fluid. Transient improvement of the pleural effusion was observed after administration of combination chemotherapy of vincristine, melphalan, cyclophosphamide, prednisone (VMCP)/vincristine, cyclophosphamide, adriamycin, prednisone (VCAP). Two months later, myelomatous pleural effusion recurred and no response to salvage therapy was observed. We reviewed the clinical feature of this case and literature concerning myelomatous pleural effusion.
Antineoplastic Agents, Combined/administration & dosage* ; Case Report ; Cyclophosphamide/administration & dosage ; Female ; Human ; Melphalan/administration & dosage ; Middle Age ; Multiple Myeloma/pathology ; Multiple Myeloma/drug therapy* ; Multiple Myeloma/complications* ; Plasma Cells/pathology ; Pleural Effusion/radiography ; Pleural Effusion/pathology ; Pleural Effusion/etiology* ; Prednisone/administration & dosage ; Tomography, X-Ray Computed ; Vincristine/administration & dosage